Discovery and Optimization of First-in-Class Furopyrimidine-Based Inhibitors of Henipaviruses
Journal of Medicinal Chemistry · 22.01.2026 · 69 (2) · 1264-1285
DOI: 10.1021/acs.jmedchem.5c02646 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Medicinal Chemistry, online erschienen am 06.01.2026. Verfasst von Irina N Gaisina und 20 weiteren Autor:innen. Beteiligte Einrichtung: UICentre: Drug Discovery, University of Illinois Chicago, Chicago, Illinois 60612, United States. Hauptthemen laut MEDLINE: Antiviral Agents, Pyrimidines, Drug Discovery, Henipavirus. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 52 Literaturangaben. Gefördert von: National Institute of Allergy and Infectious Diseases, Bill and Melinda Gates Foundation.
Abstract (Originalsprache)
Henipaviruses such as Nipah (NiV) and Hendra (HeV) are zoonotic pathogens that cause severe and often fatal respiratory illness and encephalitis in both animals and humans. These viruses exhibit high transmissibility and pandemic potential, a situation made worse by the absence of appropriate pharmaceutical countermeasures. To address this deficit, we conducted a hit-to-lead optimization campaign based on hit 1 identified through high-throughput screening against recombinant Cedar virus (rCedV), a nonpathogenic surrogate for NiV and HeV. This effort yielded a focused library of analogs that were initially screened against rCedV, with promising candidates subsequently validated against authentic NiV and HeV. Among these, analog 46 demonstrated superior in vitro metabolic stability and pharmacokinetic properties relative to hit 1 and is now positioned for in vivo efficacy evaluation. Concurrently, the mechanism of action of these first-in-class furopyrimidine-based antiviral agents was probed through time-of-addition assays, escape mutation analysis, and preliminary in silico modeling.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- UICentre: Drug Discovery, University of Illinois Chicago, Chicago, Illinois 60612, United States.
- Department of Pharmaceutical Sciences, University of Illinois Chicago, Chicago, Illinois 60612, United States.
- Chicago BioSolutions Inc., Chicago, Illinois 60612, United States.
- Department of Microbiology and Immunology, University of Illinois Chicago, Chicago, Illinois 60612, United States.
- Department of Microbiology and Immunology, University of Texas Medical Branch, Galveston, Texas 77555, United States.
- Department of Microbiology and Immunology, Uniformed Services University, Bethesda, Maryland 20814, United States.
ORCID-Profile: Irina N Gaisina, Malaika D Argade, Jazmin M Galván Achi, Christian A Zielinski, Dejan Nikolic, Paul R Carlier, Manu Anantpadma, Terry W Moore
Förderung
- National Institute of Allergy and Infectious Diseases
- Bill and Melinda Gates Foundation
Zitieren
APA
Gaisina, I. N., Argade, M. D., Bott, R., Bradley, S. P., Tomorowicz, Ł., Alvarez, M., Galván Achi, J. M., Cross, R. W., Borisevich, V., O'Toole, R., Amaya, M., Zielinski, C. A., Gaisin, A. M., Nikolic, D., Carlier, P. R., Anantpadma, M., Moore, T. W., Broder, C. C., Geisbert, T. W., …, & Rong, L. (2026). Discovery and Optimization of First-in-Class Furopyrimidine-Based Inhibitors of Henipaviruses. Journal of Medicinal Chemistry, 69(2), 1264-1285. https://doi.org/10.1021/acs.jmedchem.5c02646
Vancouver
Gaisina IN, Argade MD, Bott R, Bradley SP, Tomorowicz Ł, Alvarez M, et al. Discovery and Optimization of First-in-Class Furopyrimidine-Based Inhibitors of Henipaviruses. Journal of Medicinal Chemistry. 2026;69(2):1264-1285. doi:10.1021/acs.jmedchem.5c02646
BibTeX
@article{Gaisina2026,
author = {Gaisina, Irina N and Argade, Malaika D and Bott, Ryan and Bradley, Sean P and Tomorowicz, Łukasz and Alvarez, Mario and Galván Achi, Jazmin M and Cross, Robert W and Borisevich, Viktoriya and O'Toole, Rachel and Amaya, Moushimi and Zielinski, Christian A and Gaisin, Arsen M and Nikolic, Dejan and Carlier, Paul R and Anantpadma, Manu and Moore, Terry W and Broder, Christopher C and Geisbert, Thomas W and Peet, Norton P and Rong, Lijun},
title = {Discovery and Optimization of First-in-Class Furopyrimidine-Based Inhibitors of Henipaviruses},
journal = {Journal of Medicinal Chemistry},
year = {2026},
volume = {69},
number = {2},
pages = {1264--1285},
doi = {10.1021/acs.jmedchem.5c02646}
}
EUVIMED